The Oncology Institute, Inc. TOI Clinical trials & other — Direct costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s clinical trials & other — direct costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s clinical trials & other — direct costs?
- The Oncology Institute, Inc. (TOI) reported clinical trials & other — direct costs of $0 in Q1 2026.
- How has The Oncology Institute, Inc.'s clinical trials & other — direct costs changed year-over-year?
- The Oncology Institute, Inc.'s clinical trials & other — direct costs decreased by 100.0% year-over-year, from $214K to $0.
- What is the long-term trend for The Oncology Institute, Inc.'s clinical trials & other — direct costs?
- Over 3 years (2021 to 2024), The Oncology Institute, Inc.'s clinical trials & other — direct costs has grown at a 26.0% compound annual growth rate (CAGR), from $652K to $1.3M.
- What does clinical trials & other — direct costs mean?
- This metric identifies the specific costs directly tied to the execution of clinical trials and other related services, such as labor, materials, and specialized testing fees. Monitoring these costs is essential for evaluating the gross margin and profitability of the segment's service offerings.